导师风采
王孟昭
个人信息
Personal Information
- 性别：男
- 导师类型：博导
- 职称：主任医师
- 该职称任职时间：1997-08-21
联系方式
Contact Information
- 所属院系：北京协和医院
- 所属专业：
- 邮箱 : mengzhaowang@sina.com
- 工作电话 : 13911235467
个人简介
Personal Profile
王孟昭，北京协和医院呼吸内科肺癌中心负责人，主任医师，博士研究生导师。长期从事肺癌的多学科综合治疗，掌握国际肺癌治疗的最新方法和研究动向。
团队简介
Team Profile
王孟昭，北京协和医院呼吸内科肺癌中心负责人，主任医师，博士研究生导师。长期从事肺癌的多学科综合治疗，掌握国际肺癌治疗的最新方法和研究动向。
- 研究方向Research Directions
肺癌综合诊治
- 在校研究生Current Graduate Students
硕士研究生 0 名，博士研究生 4 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 多中心肺癌队列研究和后结构化数据队列 | 2022-10-01 —— 2025-09-01 | 主持的企业/行业委托重大项目 | 主持人 | |
| 2 | 关于阿兹夫定用于治疗有潜在进展为危重症新冠感染风险患 者的多中心随机双盲安慰剂对照研究 | 2023-06-01 —— 2025-05-01 | 主持在研的国家或省部级科研项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib | CANCER MANAGEMENT AND RESEARCH | 2019-09-01 | 通讯作者 |
| 2 | Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China：A prospective observational study | Thoracic Cancer | 2019-05-29 | 通讯作者 |
| 3 | Clinicopathological characteristics of lung cancer in patients with systemic sclerosis | CLINICAL RESPIRATORY JOURNAL | 2020-09-01 | 通讯作者 |
| 4 | Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria | THORACIC CANCER | 2020-04-01 | 通讯作者 |
| 5 | Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis | THORACIC CANCER | 2020-07-01 | 通讯作者 |
| 6 | Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer | ESMO OPEN | 2020-07-01 | 通讯作者 |
| 7 | Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments | Translational Lung Cancer Research | 2021-12-10 | 通讯作者 |
| 8 | Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China | Thoracic Cancer | 2022-02-13 | 通讯作者 |
| 9 | Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy | Thoracic Cancer | 2022-02-13 | 通讯作者 |
| 10 | Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China | Frontiers in Oncology | 2022-03-15 | 通讯作者 |
| 11 | Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study | Frontiers in Oncology | 2022-04-26 | 通讯作者 |
| 12 | Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer | Frontiers in Immunology | 2022-03-09 | 通讯作者 |
| 13 | Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer | THORACIC CANCER | 2021-07-01 | 通讯作者 |
| 14 | Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus | Translational Oncology | 2022-10-16 | 通讯作者 |
| 15 | Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study | Translational Lung Cancer Research | 2022-07-07 | 通讯作者 |
| 16 | Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer | Frontiers in Immunology | 2022-07-23 | 通讯作者 |
| 17 | Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer | THORACIC CANCER | 2023-02-14 | 通讯作者 |
| 18 | The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer | THORACIC CANCER | 2023-01-02 | 通讯作者 |
| 19 | Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel | Journal of Thoracic Disease | 2022-12-30 | 通讯作者 |
| 20 | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment | CLINICAL AND EXPERIMENTAL MEDICINE | 2023-01-30 | 通讯作者 |
| 21 | Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases | Translational Oncology | 2023-05-31 | 通讯作者 |
| 22 | Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy | Thoracic Cancer | 2023-03-01 | 通讯作者 |
| 23 | All-shot Aspirations in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Are Associated With Malignancy | TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023-04-20 | 通讯作者 |
| 24 | Risk factors for immune-related adverse events: what have we learned and what lies ahead? | Biomarker Research | 2021-11-03 | 通讯作者 |
| 25 | MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis | ONCOTARGETS AND THERAPY | 2020-03-01 | 通讯作者 |
| 26 | Recognition and management of the gastrointestinal and hepatic immune-related adverse events | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020-06-01 | 通讯作者 |
| 27 | Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020-08-01 | 通讯作者 |
| 28 | Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer | Cancer Management and Research | 2019-08-15 | 通讯作者 |
| 29 | Clinical recommendations on lung cancer management during the COVID-19 pandemic | THORACIC CANCER | 2020-07-01 | 通讯作者 |
| 30 | Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC | Thoracic Cancer | 2023-11-15 | 通讯作者 |
| 31 | Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma | Journal for ImmunoTherapy of Cancer | 2023-10-19 | 通讯作者 |
| 32 | Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study | Translational Lung Cancer Research | 2023-11-30 | 通讯作者 |
| 33 | The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study | Journal of Clinical Medicine | 2024-01-01 | 通讯作者 |
| 34 | Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial | Lancet Respiratory Medicine | 2024-03-01 | 通讯作者 |
| 35 | The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China | Cancer Medicine | 2024-01-05 | 通讯作者 |
| 36 | Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial | Trials | 2024-01-22 | 通讯作者 |
| 37 | Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers | CANCER GENE THERAPY | 2024-05-18 | 通讯作者 |
| 38 | Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster | EMERGING MICROBES & INFECTIONS | 2020-01-01 | 通讯作者 |
| 39 | Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Cancer Discovery | 2022-07-01 | 第一作者 |
- 科研获奖Research Awards
无
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | 呼吸与危重症专科医师培训精要 |